Q-omics provides the consensus-scored ANKRD20A1 profile across patient tissues and cancer cell-line models. ANKRD20A1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, ANKRD20A1 is differentially expressed in 7, with the highest sampling consensus in THCA. Additionally, ANKRD20A1 RNA expression shows 14,834 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight CESC, THCA, and THYM as cancer lineages where ANKRD20A1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANKRD20A1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANKRD20A1 survival associations across molecular data types. ANKRD20A1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANKRD20A1 RNA expression–survival associations across cancer types. High ANKRD20A1 expression shows unfavorable associations in THCA and ACC, but favorable associations in CESC, SKCM, KIRC and STAD. The CESC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify CESC as the clearest survival context for ANKRD20A1 RNA expression.
This table summarizes ANKRD20A1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ANKRD20A1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANKRD20A1 shows lower tumor expression in THCA, BRCA, COAD, HNSC and LUAD and higher tumor expression in KIRC. The THCA box plot shows higher ANKRD20A1 RNA expression in normal versus tumor tissue (log2 FC = −0.080, t-test p < 0.001).
This table shows molecular features associated with ANKRD20A1 in patient tissues and cancer cell lines. In patient samples, ANKRD20A1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ANKRD20A1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia.
